Analysts Stocks

      Morgan Stanley Downgrades RXO to Equal-Weight, PT $22

      Morgan Stanley analyst Ravi Shanker raised their price target on RXO to $22 on May 8, downgrading the rating to Equal-Weight from Overweight.

      Ravi has made 18 price-target calls on RXO that AnaChart has tracked. 18 of 18 were touched by the stock’s price at some point after the call.

      The rating count on RXO runs 4 Buy, 7 Hold, 1 Sell right now. Citi‘s Ariel Rosa holds the high end of the range at $30; Goldman Sachs‘s Jordan Alliger anchors the low end at $15. The stock’s most recent close was $26.85.

      RXO price target chart: Morgan Stanley raises to $22
      Ravi Shanker’s RXO target history against the street high, street low and the stock price. Each dot marks a dated call.

      The $22 target is 18% below the stock’s $26.85 close.

      FAQ

      What is Morgan Stanley’s price target on RXO?

      Morgan Stanley’s Ravi Shanker has a $22 target on RXO, rated Equal-Weight, set May 8, 2026.

      How often have Ravi Shanker’s RXO price targets been reached?

      AnaChart has tracked 18 price-target calls from Ravi Shanker on RXO; the stock reached the target in 18 of them (100%).

      What is the analyst view on RXO?

      Coverage is split 4 Buy / 7 Hold / 1 Sell, with targets from $15 (Goldman Sachs) to $30 (Citi).